On August 20, 2009
Bayer Loses Nexavar Case in India; Could Open Door to Easier Generic Approvals
Bayer has lost an attempt in the high court in Delhi to link new drug approvals to the validity of patent exclusivity. Depending on your point of view, the ruling either potentially opens the door for Indian generic manufacturers like Cipla, Dr Reddy’s and Ranbaxy to decimate the branded drug market there; or gives Indian patients quicker access to cheap drugs.
0 Comments